Abbott Laboratories (ABT) EBIAT (2009 - 2026)

Abbott Laboratories' EBIAT history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, EBIAT fell 18.72% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $6.3 billion (down 53.52% YoY), while the FY2025 annual figure was $6.5 billion, down 51.32% from the prior year.
• EBIAT came in at $1.1 billion for Q1 2026 at Abbott Laboratories, down from $1.8 billion in the prior quarter.
• In the past five years, EBIAT ranged from a high of $9.2 billion in Q4 2024 to a low of $1.0 billion in Q4 2022.
• A 5-year average of $2.0 billion and a median of $1.4 billion in 2023 frame the typical range for EBIAT.
• Across the five-year window, EBIAT surged 478.98% in 2024 and plunged 80.76% in 2025, its largest moves.
• Abbott Laboratories' EBIAT stood at $1.0 billion in 2022, then surged by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then slumped by 80.76% to $1.8 billion in 2025, then sank by 39.36% to $1.1 billion in 2026.
• According to Business Quant data, EBIAT over the past three periods registered $1.1 billion, $1.8 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison